Your browser doesn't support javascript.
loading
Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma.
Watz, Henrik; Uddin, Mohib; Pedersen, Frauke; Kirsten, Anne; Goldmann, Torsten; Stellmacher, Florian; Groth, Espen; Larsson, Bengt; Böttcher, Gerhard; Malmgren, Anna; Kraan, Maarten; Rabe, Klaus F.
Afiliação
  • Watz H; Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany. Electronic address: h.watz@pulmoresearch.de.
  • Uddin M; Respiratory, Inflammation & Autoimmunity, Innovative Medicines and Early Development, AstraZeneca, Gothenburg, 431 83, Sweden.
  • Pedersen F; Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
  • Kirsten A; Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
  • Goldmann T; Pathology of the University Luebeck and the Research Center Borstel, Site Borstel, Clinical and Experimental Pathology, Borstel, Airway Research Center North, German Center for Lung Research, Borstel, Germany.
  • Stellmacher F; Pathology of the University Luebeck and the Research Center Borstel, Site Borstel, Clinical and Experimental Pathology, Borstel, Airway Research Center North, German Center for Lung Research, Borstel, Germany.
  • Groth E; Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Pathology of the University Luebeck and the Research Center Borstel, Site Borstel, Clinical and Experimental Pathology, Borstel, Airway Research Center North, German Center for Lung Rese
  • Larsson B; Translational Medicine Unit, Early Clinical Development, Innovative Medicines and Early Development, AstraZeneca, Pepparedsleden 1, Gothenburg, 431 83, Sweden.
  • Böttcher G; Drug Safety and Metabolism, Innovative Medicines and Early Development, AstraZeneca, Pepparedsleden 1, Gothenburg, 431 83, Sweden.
  • Malmgren A; Respiratory, Inflammation & Autoimmunity, Innovative Medicines and Early Development, AstraZeneca, Gothenburg, 431 83, Sweden.
  • Kraan M; Respiratory, Inflammation & Autoimmunity, Innovative Medicines and Early Development, AstraZeneca, Gothenburg, 431 83, Sweden.
  • Rabe KF; Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
Pulm Pharmacol Ther ; 45: 121-123, 2017 08.
Article em En | MEDLINE | ID: mdl-28549850
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Asma / Sulfonamidas / Infiltração de Neutrófilos / Receptores de Interleucina-8B Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Asma / Sulfonamidas / Infiltração de Neutrófilos / Receptores de Interleucina-8B Idioma: En Ano de publicação: 2017 Tipo de documento: Article